Iron homeostasis in health and disease

International Journal of Molecular Sciences

Volumn 17, Issue 1, 2016, Pages 2-14

  Gozzelino, Raffaella ^a   Arosio, Paolo ^b  

^a UNIVERSITY OF LISBON   (Portugal)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Iron; Iron metabolism; Iron toxicity

Indexed keywords

HEME; HEPCIDIN; IRON; LOW DENSITY LIPOPROTEIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; REACTIVE OXYGEN METABOLITE; CATION TRANSPORT PROTEIN; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; IRP1 PROTEIN, HUMAN; IRP2 PROTEIN, HUMAN; METAL TRANSPORTING PROTEIN 1;

AGING; ANEMIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DNA DAMAGE; ERYTHROPOIESIS; HEMOCHROMATOSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; IRON DEFICIENCY; IRON HOMEOSTASIS; IRON METABOLISM; META ANALYSIS (TOPIC); NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; REVIEW; TUMOR GROWTH; ANIMAL; DNA RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; GENETICS; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

AGING; ANEMIA, IRON-DEFICIENCY; ANIMALS; CATION TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HEME; HEMOCHROMATOSIS; HEPCIDINS; HOMEOSTASIS; HUMANS; IRON; IRON OVERLOAD; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION;

EID: 84955059552     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17010130     Document Type: Review

References (112)

1. Zhao, L.; Xia, Z.; Wang, F. Zebrafish in the sea of mineral (iron, zinc, and copper) metabolism. Front. Pharmacol. 2014, 5, 33. [CrossRef] [PubMed]
2. Loreal, O.; Cavey, T.; Bardou-Jacquet, E.; Guggenbuhl, P.; Ropert, M.; Brissot, P. Iron, hepcidin, and the metal connection. Front. Pharmacol. 2014, 5, 128. [PubMed]
3. Fenton, H.J.H. Oxidation of tartaric acid in presence of iron. J. Chem. Soc. 1894, 65, 899–910. [CrossRef]
4. Zhang, C. Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell 2014, 5, 750–760. [CrossRef] [PubMed]
5. Paul, V.D.; Lill, R. Biogenesis of cytosolic and nuclear iron–sulfur proteins and their role in genome stability. Biochim. Biophys. Acta 2015, 1853, 1528–1539. [CrossRef] [PubMed]
6. Gozzelino, R.; Arosio, P. The importance of iron in pathophysiologic conditions. Front. Pharmacol. 2015, 6, 6. [CrossRef] [PubMed]
7. Andrews, N.C.; Schmidt, P.J. Iron homeostasis. Annu. Rev. Physiol. 2007, 69, 69–85. [CrossRef] [PubMed]
8. Meyron-Holtz, E.G.; Cohen, L.A.; Fahoum, L.; Haimovich, Y.; Lifshitz, L.; Magid-Gold, I.; Stuemler, T.; Truman-Rosentsvit, M. Ferritin polarization and iron transport across monolayer epithelial barriers in mammals. Front. Pharmacol. 2014, 5, 194. [CrossRef] [PubMed]
9. Philpott, C.C.; Ryu, M.S. Special delivery: Distributing iron in the cytosol of mammalian cells. Front. Pharmacol. 2014, 5, 173. [CrossRef] [PubMed]
10. Collingwood, J.F.; Davidson, M.R. The role of iron in neurodegenerative disorders: Insights and opportunities with synchrotron light. Front. Pharmacol. 2014, 5, 191. [CrossRef] [PubMed]
11. Baksi, A.J.; Pennell, D.J. Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major. Front. Pharmacol. 2014, 5, 217. [CrossRef] [PubMed]
12. Cabantchik, Z.I. Labile iron in cells and body fluids: Physiology, pathology, and pharmacology. Front. Pharmacol. 2014, 5, 45. [CrossRef] [PubMed]
13. Zhang, D.L.; Ghosh, M.C.; Rouault, T.A. The physiological functions of iron regulatory proteins in iron homeostasis—An update. Front. Pharmacol. 2014, 5, 124. [CrossRef] [PubMed]
14. Wright, J.A.; Richards, T.; Srai, S.K. The role of iron in the skin and cutaneous wound healing. Front. Pharmacol. 2014, 5, 156. [CrossRef] [PubMed]
15. Worthen, C.A.; Enns, C.A. The role of hepatic transferrin receptor 2 in the regulation of iron homeostasis in the body. Front. Pharmacol. 2014, 5, 34. [CrossRef] [PubMed]
16. Anderson, C.P.; Leibold, E.A. Mechanisms of iron metabolism in caenorhabditis elegans. Front. Pharmacol. 2014, 5, 113. [CrossRef] [PubMed]
17. Veuthey, T.; Wessling-Resnick, M. Pathophysiology of the belgrade rat. Front. Pharmacol. 2014, 5, 82. [CrossRef] [PubMed]
18. Torti, F.M.; Torti, S.V. Regulation of ferritin genes and protein. Blood 2002, 99, 3505–3516. [CrossRef] [PubMed]
19. Arosio, P.; Carmona, F.; Gozzelino, R.; Maccarinelli, F.; Poli, M. The importance of eukaryotic ferritins in iron handling and cytoprotection. Biochem. J. 2015, 472, 1–15. [CrossRef] [PubMed]
20. Drakesmith, H.; Nemeth, E.; Ganz, T. Ironing out ferroportin. Cell Metab. 2015, 22, 777–787. [CrossRef] [PubMed]
21. Ohgami, R.S.; Campagna, D.R.; Greer, E.L.; Antiochos, B.; McDonald, A.; Chen, J.; Sharp, J.J.; Fujiwara, Y.; Barker, J.E.; Fleming, M.D. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet. 2005, 37, 1264–1269. [CrossRef] [PubMed]
22. Sendamarai, A.K.; Ohgami, R.S.; Fleming, M.D.; Lawrence, C.M. Structure of the membrane proximal oxidoreductase domain of human steap3, the dominant ferrireductase of the erythroid transferrin cycle. Proc. Natl. Acad. Sci. USA 2008, 105, 7410–7415. [CrossRef] [PubMed]
23. Kautz, L.; Jung, G.; Valore, E.V.; Rivella, S.; Nemeth, E.; Ganz, T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 2014, 46, 678–684. [CrossRef] [PubMed]
24. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090–2093. [CrossRef] [PubMed]
25. Kim, A.; Nemeth, E. New insights into iron regulation and erythropoiesis. Curr. Opin. Hematol. 2015, 22, 199–205. [CrossRef] [PubMed]
26. Ganz, T.; Nemeth, E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta 2012, 1823, 1434–1443. [CrossRef] [PubMed]
27. Ponka, P. Cell biology of heme. Am. J. Med. Sci. 1999, 318, 241–256. [CrossRef]
28. Larsen, R.; Gouveia, Z.; Soares, M.P.; Gozzelino, R. Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases. Front. Pharmacol. 2012, 3, 77. [CrossRef] [PubMed]
29. Gozzelino, R.; Soares, M.P. Heme sensitization to TNF-mediated programmed cell death. Adv. Exp. Med. Biol. 2011, 691, 211–219.
30. Dutra, F.F.; Bozza, M.T. Heme on innate immunity and inflammation. Front. Pharmacol. 2014, 5, 115. [CrossRef] [PubMed]
31. Gozzelino, R.; Soares, M.P. Coupling heme and iron metabolism via ferritin H chain. Antioxid. Redox Signal. 2014, 20, 1754–1769. [CrossRef] [PubMed]
32. Schaer, D.J.; Vinchi, F.; Ingoglia, G.; Tolosano, E.; Buehler, P.W. Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. Front. Physiol. 2014, 5, 415. [CrossRef] [PubMed]
33. Smith, A.; McCulloh, R.J. Hemopexin and haptoglobin: Allies against heme toxicity from hemoglobin not contenders. Front. Physiol. 2015, 6, 187. [CrossRef] [PubMed]
34. Chiabrando, D.; Marro, S.; Mercurio, S.; Giorgi, C.; Petrillo, S.; Vinchi, F.; Fiorito, V.; Fagoonee, S.; Camporeale, A.; Turco, E.; et al. The mitochondrial heme exporter flvcr1b mediates erythroid differentiation. J. Clin. Investig. 2012, 122, 4569–4579. [CrossRef] [PubMed]
35. Keel, S.B.; Doty, R.T.; Yang, Z.; Quigley, J.G.; Chen, J.; Knoblaugh, S.; Kingsley, P.D.; de Domenico, I.; Vaughn, M.B.; Kaplan, J.; et al. A heme export protein is required for red blood cell differentiation and iron homeostasis. Science 2008, 319, 825–828. [CrossRef] [PubMed]
36. Krishnamurthy, P.; Ross, D.D.; Nakanishi, T.; Bailey-Dell, K.; Zhou, S.; Mercer, K.E.; Sarkadi, B.; Sorrentino, B.P.; Schuetz, J.D. The stem cell marker BCRP/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 2004, 279, 24218–24225. [CrossRef] [PubMed]
37. Latunde-Dada, G.O.; Laftah, A.H.; Masaratana, P.; McKie, A.T.; Simpson, R.J. Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis. Front. Pharmacol. 2014, 5, 135. [CrossRef] [PubMed]
38. Rajagopal, A.; Rao, A.U.; Amigo, J.; Tian, M.; Upadhyay, S.K.; Hall, C.; Uhm, S.; Mathew, M.K.; Fleming, M.D.; Paw, B.H.; et al. Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins. Nature 2008, 453, 1127–1131. [CrossRef] [PubMed]
39. Korolnek, T.; Hamza, I. Like iron in the blood of the people: The requirement for heme trafficking in iron metabolism. Front. Pharmacol. 2014, 5, 126. [CrossRef] [PubMed]
40. Chiabrando, D.; Vinchi, F.; Fiorito, V.; Mercurio, S.; Tolosano, E. Heme in pathophysiology: A matter of scavenging, metabolism and trafficking across cell membranes. Front. Pharmacol. 2014, 5, 61. [PubMed]
41. Silvestri, L.; Nai, A.; Pagani, A.; Camaschella, C. The extrahepatic role of TFR2 in iron homeostasis. Front. Pharmacol. 2014, 5, 93. [CrossRef] [PubMed]
42. Vujic, M. Molecular basis of HFE-hemochromatosis. Front. Pharmacol. 2014, 5, 42. [PubMed]
43. Donovan, A.; Lima, C.A.; Pinkus, J.L.; Pinkus, G.S.; Zon, L.I.; Robine, S.; Andrews, N.C. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005, 1, 191–200. [CrossRef] [PubMed]
44. Pietrangelo, A. The ferroportin disease. Blood Cells Mol. Dis. 2004, 32, 131–138. [CrossRef] [PubMed]
45. Core, A.B.; Canali, S.; Babitt, J.L. Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front. Pharmacol. 2014, 5, 104. [CrossRef] [PubMed]
46. Sham, R.L.; Phatak, P.D.; West, C.; Lee, P.; Andrews, C.; Beutler, E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol. Dis. 2005, 34, 157–161. [CrossRef] [PubMed]
47. Fernandes, A.; Preza, G.C.; Phung, Y.; de Domenico, I.; Kaplan, J.; Ganz, T.; Nemeth, E. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood 2009, 114, 437–443. [CrossRef] [PubMed]
48. Pietrangelo, A. Hereditary hemochromatosis: Pathogenesis, diagnosis, and treatment. Gastroenterology 2010, 139, 393–408, 408 e1–408 e2. [CrossRef] [PubMed]
49. Altamura, S.; Kessler, R.; Grone, H.J.; Gretz, N.; Hentze, M.W.; Galy, B.; Muckenthaler, M.U. Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload. Cell Metab. 2014, 20, 359–367. [CrossRef] [PubMed]
50. Lopez, A.; Cacoub, P.; Macdougall, I.C.; Peyrin-Biroulet, L. Iron deficiency anaemia. Lancet 2015. [CrossRef]
51. Clark, M.A.; Goheen, M.M.; Cerami, C. Influence of host iron status on plasmodium falciparum infection. Front. Pharmacol. 2014, 5, 84. [CrossRef] [PubMed]
52. Sankaran, V.G.; Weiss, M.J. Anemia: Progress in molecular mechanisms and therapies. Nat. Med. 2015, 21, 221–230. [CrossRef] [PubMed]
53. Deans, A.J.; West, S.C. Fancm connects the genome instability disorders bloom’s syndrome and fanconi anemia. Mol. Cell 2009, 36, 943–953. [CrossRef] [PubMed]
54. Wang, C.Y.; Meynard, D.; Lin, H.Y. The role of TMPRSS6/matriptase-2 in iron regulation and anemia. Front. Pharmacol. 2014, 5, 114. [CrossRef] [PubMed]
55. Busti, F.; Campostrini, N.; Martinelli, N.; Girelli, D. Iron deficiency in the elderly population, revisited in the hepcidin era. Front. Pharmacol. 2014, 5, 83. [CrossRef] [PubMed]
56. Nemeth, E.; Ganz, T. Anemia of inflammation. Hematol. Oncol. Clin. N. Am. 2014, 28, 671–681. [CrossRef] [PubMed]
57. Kautz, L.; Jung, G.; Du, X.; Gabayan, V.; Chapman, J.; Nasoff, M.; Nemeth, E.; Ganz, T. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of _-thalassemia. Blood 2015, 126, 2031–2037. [CrossRef] [PubMed]
58. Poli, M.; Asperti, M.; Ruzzenenti, P.; Regoni, M.; Arosio, P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front. Pharmacol. 2014, 5, 86. [CrossRef] [PubMed]
59. Knight, K.; Wade, S.; Balducci, L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am. J. Med. 2004, 116, 11S–26S. [CrossRef] [PubMed]
60. Dicato, M.; Plawny, L.; Diederich, M. Anemia in cancer. Ann. Oncol. 2010, 21, vii167–172. [CrossRef] [PubMed]
61. Torti, S.V.; Torti, F.M. Ironing out cancer. Cancer Res. 2011, 71, 1511–1514. [CrossRef] [PubMed]
62. Munoz, M.; Gomez-Ramirez, S.; Martin-Montanez, E.; Auerbach, M. Perioperative anemia management in colorectal cancer patients: A pragmatic approach. World J. Gastroenterol. WJG 2014, 20, 1972–1985. [CrossRef] [PubMed]
63. Kukulj, S.; Jaganjac, M.; Boranic, M.; Krizanac, S.; Santic, Z.; Poljak-Blazi, M. Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med. Oncol. 2010, 27, 268–277. [CrossRef] [PubMed]
64. Xiong, W.; Wang, L.; Yu, F. Regulation of cellular iron metabolism and its implications in lung cancer progression. Med. Oncol. 2014, 31, 28. [CrossRef] [PubMed]
65. Aleman, M.R.; Santolaria, F.; Batista, N.; de La Vega, M.; Gonzalez-Reimers, E.; Milena, A.; Llanos, M.; Gomez-Sirvent, J.L. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 2002, 19, 21–26. [CrossRef] [PubMed]
66. Orlandi, R.; de Bortoli, M.; Ciniselli, C.M.; Vaghi, E.; Caccia, D.; Garrisi, V.; Pizzamiglio, S.; Veneroni, S.; Bonini, C.; Agresti, R.; et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann. Oncol. 2014, 25, 352–357. [CrossRef] [PubMed]
67. Zhang, C.; Zhang, F. Iron homeostasis and tumorigenesis: Molecular mechanisms and therapeutic opportunities. Protein Cell 2015, 6, 88–100. [CrossRef] [PubMed]
68. Wu, T.; Sempos, C.T.; Freudenheim, J.L.; Muti, P.; Smit, E. Serum iron, copper and zinc concentrations and risk of cancer mortality in us adults. Ann. Epidemiol. 2004, 14, 195–201. [CrossRef]
69. Van Asperen, I.A.; Feskens, E.J.; Bowles, C.H.; Kromhout, D. Body iron stores and mortality due to cancer and ischaemic heart disease: A 17-year follow-up study of elderly men and women. Int. J. Epidemiol. 1995, 24, 665–670. [CrossRef] [PubMed]
70. Caro, J.J.; Salas, M.; Ward, A.; Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001, 91, 2214–2221. [CrossRef]
71. Torti, S.V.; Torti, F.M. Iron and cancer: More ore to be mined. Nat. Rev. Cancer 2013, 13, 342–355. [CrossRef] [PubMed]
72. Inoue, S.; Kawanishi, S. Hydroxyl radical production and human DNA damage induced by ferric nitrilotriacetate and hydrogen peroxide. Cancer Res. 1987, 47, 6522–6527. [PubMed]
73. Dizdaroglu, M.; Rao, G.; Halliwell, B.; Gajewski, E. Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. Arch. Biochem. Biophys. 1991, 285, 317–324. [CrossRef]
74. Dizdaroglu, M.; Jaruga, P. Mechanisms of free radical-induced damage to DNA. Free Radic. Res. 2012, 46, 382–419. [CrossRef] [PubMed]
75. Toyokuni, S. Molecular mechanisms of oxidative stress-induced carcinogenesis: From epidemiology to oxygenomics. IUBMB Life 2008, 60, 441–447. [CrossRef] [PubMed]
76. Landskron, G.; de la Fuente, M.; Thuwajit, P.; Thuwajit, C.; Hermoso, M.A. Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 2014, 149185. [CrossRef] [PubMed]
77. Silva-Santos, B.; Serre, K.; Norell, H. Gammadelta T cells in cancer. Nat. Rev. Immunol. 2015, 15, 683–691. [CrossRef] [PubMed]
78. Kitamura, T.; Qian, B.Z.; Pollard, J.W. Immune cell promotion of metastasis. Nat. Rev. Immunol. 2015, 15.
79. Ganz, T.; Nemeth, E. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 2015, 15, 500–510. [CrossRef] [PubMed]
80. Soares, M.P.; Weiss, G. The iron age of host-microbe interactions. EMBO Rep. 2015, 16, 1482–1500. [CrossRef] [PubMed]
81. Kosmidis, S.; Missirlis, F.; Botella, J.A.; Schneuwly, S.; Rouault, T.A.; Skoulakis, E.M. Behavioral decline and premature lethality upon pan-neuronal ferritin overexpression in Drosophila infected with a virulent form of wolbachia. Front. Pharmacol. 2014, 5, 66. [CrossRef] [PubMed]
82. Drakesmith, H.; Prentice, A.M. Hepcidin and the iron-infection axis. Science 2012, 338, 768–772. [CrossRef] [PubMed]
83. Pinto, J.P.; Arezes, J.; Dias, V.; Oliveira, S.; Vieira, I.; Costa, M.; Vos, M.; Carlsson, A.; Rikers, Y.; Rangel, M.; et al. Physiological implications of NTBI uptake by t lymphocytes. Front. Pharmacol. 2014, 5, 24. [CrossRef] [PubMed]
84. Nairz, M.; Haschka, D.; Demetz, E.;Weiss, G. Iron at the interface of immunity and infection. Front. Pharmacol. 2014, 5, 152. [CrossRef] [PubMed]
85. Spottiswoode, N.; Duffy, P.E.; Drakesmith, H. Iron, anemia and hepcidin in malaria. Front. Pharmacol. 2014, 5, 125. [CrossRef] [PubMed]
86. Portugal, S.; Carret, C.; Recker, M.; Armitage, A.E.; Goncalves, L.A.; Epiphanio, S.; Sullivan, D.; Roy, C.; Newbold, C.I.; Drakesmith, H.; et al. Host-mediated regulation of superinfection in malaria. Nat. Med. 2011, 17, 732–737. [CrossRef] [PubMed]
87. Penha-Goncalves, C.; Gozzelino, R.; de Moraes, L.V. Iron overload in Plasmodium berghei-infected placenta as a pathogenesis mechanism of fetal death. Front. Pharmacol. 2014, 5, 155. [PubMed]
88. Vercellotti, G.M.; Khan, F.B.; Nguyen, J.; Chen, C.; Bruzzone, C.M.; Bechtel, H.; Brown, G.; Nath, K.A.; Steer, C.J.; Hebbel, R.P.; et al. H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice. Front. Pharmacol. 2014, 5, 79. [CrossRef] [PubMed]
89. Gammella, E.; Maccarinelli, F.; Buratti, P.; Recalcati, S.; Cairo, G. The role of iron in anthracycline cardiotoxicity. Front. Pharmacol. 2014, 5, 25. [CrossRef] [PubMed]
90. Basuli, D.; Stevens, R.G.; Torti, F.M.; Torti, S.V. Epidemiological associations between iron and cardiovascular disease and diabetes. Front. Pharmacol. 2014, 5, 117. [PubMed]
91. Sullivan, J.L. Iron and the sex difference in heart disease risk. Lancet 1981, 1, 1293–1294. [CrossRef]
92. Sullivan, J.L. The iron paradigm of ischemic heart disease. Am. Heart J. 1989, 117, 1177–1188. [CrossRef]
93. Vinchi, F.; Muckenthaler, M.U.; da Silva, M.C.; Balla, G.; Balla, J.; Jeney, V. Atherogenesis and iron: From epidemiology to cellular level. Front. Pharmacol. 2014, 5, 94. [CrossRef] [PubMed]
94. Xu, W.; Barrientos, T.; Mao, L.; Rockman, H.A.; Sauve, A.A.; Andrews, N.C. Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep. 2015, 13, 533–545. [CrossRef] [PubMed]
95. Lakhal-Littleton, S.; Wolna, M.; Carr, C.A.; Miller, J.J.; Christian, H.C.; Ball, V.; Santos, A.; Diaz, R.; Biggs, D.; Stillion, R.; et al. Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. Proc. Natl. Acad. Sci. USA 2015, 112, 3164–3169. [CrossRef] [PubMed]
96. Morrison, H.I.; Semenciw, R.M.; Mao, Y.; Wigle, D.T. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994, 5, 243–246. [CrossRef] [PubMed]
97. Holay, M.P.; Choudhary, A.A.; Suryawanshi, S.D. Serum ferritin-a novel risk factor in acute myocardial infarction. Indian Heart J. 2012, 64, 173–177. [CrossRef]
98. Menke, A.; Fernandez-Real, J.M.; Muntner, P.; Guallar, E. The association of biomarkers of iron status with peripheral arterial disease in us adults. BMC Cardiovasc. Disord. 2009, 9, 34. [CrossRef] [PubMed]
99. Lauffer, R.B. Iron depletion and coronary disease. Am. Heart J. 1990, 119, 1448–1449. [CrossRef]
100. Kiechl, S.; Willeit, J.; Egger, G.; Poewe, W.; Oberhollenzer, F. Body iron stores and the risk of carotid atherosclerosis: Prospective results from the bruneck study. Circulation 1997, 96, 3300–3307. [CrossRef] [PubMed]
101. Habib, A.; Finn, A.V. The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis. Front. Pharmacol. 2014, 5, 195. [CrossRef] [PubMed]
102. Gozzelino, R. The pathophysiology of heme in the brain. Curr. Alzheimer Res. 2015, 13, 174–184. [CrossRef]
103. Arruda, L.F.; Arruda, S.F.; Campos, N.A.; de Valencia, F.F.; Siqueira, E.M. Dietary iron concentration may influence aging process by altering oxidative stress in tissues of adult rats. PLoS ONE 2013, 8, e61058. [CrossRef] [PubMed]
104. Nelson, R.L. Iron and colorectal cancer risk: Human studies. Nutr. Rev. 2001, 59, 140–148. [CrossRef] [PubMed]
105. Wong, B.X.; Duce, J.A. The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders. Front. Pharmacol. 2014, 5, 81. [CrossRef] [PubMed]
106. Isaya, G. Mitochondrial iron–sulfur cluster dysfunction in neurodegenerative disease. Front. Pharmacol. 2014, 5, 29. [CrossRef] [PubMed]
107. Martelli, A.; Puccio, H. Dysregulation of cellular iron metabolism in friedreich ataxia: From primary iron–sulfur cluster deficit to mitochondrial iron accumulation. Front. Pharmacol. 2014, 5, 130. [CrossRef] [PubMed]
108. Ali-Rahmani, F.; Schengrund, C.L.; Connor, J.R. Hfe gene variants, iron, and lipids: A novel connection in alzheimer's disease. Front. Pharmacol. 2014, 5, 165. [CrossRef] [PubMed]
109. Levi, S.; Finazzi, D. Neurodegeneration with brain iron accumulation: Update on pathogenic mechanisms. Front. Pharmacol. 2014, 5, 99. [CrossRef] [PubMed]
110. Gao, G.; Chang, Y.Z. Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases. Front. Pharmacol. 2014, 5, 19. [CrossRef] [PubMed]
111. Urrutia, P.J.; Mena, N.P.; Nunez, M.T. The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front. Pharmacol. 2014, 5, 38. [CrossRef] [PubMed]
112. Cabantchik, Z.I.; Munnich, A.; Youdim, M.B.; Devos, D. Regional siderosis: A new challenge for iron chelation therapy. Front. Pharmacol. 2013, 4, 167. [CrossRef] [PubMed]